IQVIA Holdings Inc. $IQV Shares Acquired by Allianz SE

Allianz SE boosted its stake in IQVIA Holdings Inc. (NYSE:IQV) by 213.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,390 shares of the medical research company’s stock after acquiring an additional 2,310 shares during the period. Allianz SE’s holdings in IQVIA were worth $534,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Pacer Advisors Inc. raised its stake in shares of IQVIA by 5,036.1% in the 1st quarter. Pacer Advisors Inc. now owns 871,704 shares of the medical research company’s stock valued at $153,681,000 after purchasing an additional 854,732 shares in the last quarter. JPMorgan Chase & Co. grew its stake in IQVIA by 45.7% in the first quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company’s stock worth $448,686,000 after purchasing an additional 798,534 shares in the last quarter. Nordea Investment Management AB increased its holdings in IQVIA by 41.7% in the second quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock valued at $326,274,000 after buying an additional 606,391 shares during the last quarter. Hawk Ridge Capital Management LP bought a new position in IQVIA during the 1st quarter worth approximately $77,096,000. Finally, Nuveen LLC acquired a new position in shares of IQVIA in the 1st quarter worth approximately $76,328,000. 89.62% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the business’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the sale, the insider directly owned 27,108 shares in the company, valued at approximately $5,955,627.60. The trade was a 12.86% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.60% of the company’s stock.

IQVIA Stock Up 1.1%

Shares of IQVIA stock opened at $223.36 on Friday. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $228.12. The business’s fifty day moving average price is $202.05 and its two-hundred day moving average price is $178.04. The company has a market capitalization of $38.04 billion, a P/E ratio of 30.64, a PEG ratio of 2.47 and a beta of 1.34.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The company had revenue of $4.10 billion for the quarter, compared to analyst estimates of $4.07 billion. During the same period last year, the company earned $2.84 earnings per share. The company’s quarterly revenue was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Mizuho upped their price target on IQVIA from $190.00 to $225.00 and gave the company an “outperform” rating in a research report on Friday, July 25th. Robert W. Baird set a $258.00 target price on shares of IQVIA and gave the stock an “outperform” rating in a report on Wednesday, October 29th. UBS Group raised their price target on shares of IQVIA from $225.00 to $250.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Cowen downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Monday, November 3rd. Finally, Jefferies Financial Group raised shares of IQVIA from a “hold” rating to a “buy” rating and raised their target price for the stock from $195.00 to $225.00 in a report on Tuesday, September 9th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $241.00.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.